AstraZeneca to fully acquire Caelum Biosciences

AstraZeneca will advance and accelerate ongoing Phase III clinical development of CAEL-101, a potential first-in-class medicine for AL amyloidosis AstraZeneca’s Alexion has exercised its option to acquire all remaining equity in […]

HAWKINS 2021 WEBINAR SERIES: THE LEEDS OFFICE

Our colleagues in the Leeds Office have created a series of webinars on how Hawkins investigates topics from fire safety to fibre analysis, water woes to helmet usage, personal injuries […]